Does Finasteride Affect Testosterone Levels?

Finasteride does affect testosterone levels, but not in the direction most people expect. Rather than lowering testosterone, finasteride tends to raise it modestly by blocking the enzyme that converts testosterone into dihydrotestosterone (DHT). The size of that bump depends on your baseline hormone levels and is often small enough that you wouldn’t notice it on a blood test. The bigger hormonal story is what happens downstream: a sharp drop in DHT, subtle shifts in estrogen, and changes in brain-active steroids that researchers are still working to understand.

How Finasteride Reroutes Hormone Conversion

Testosterone doesn’t just sit in your bloodstream doing one job. A portion of it gets converted into DHT by an enzyme called 5-alpha reductase. DHT is a more potent androgen than testosterone itself, and it’s the hormone most responsible for shrinking hair follicles in male pattern hair loss and enlarging the prostate in older men. Finasteride works by competitively binding to that enzyme, essentially plugging the slot where testosterone would normally dock and be transformed.

Because the conversion pathway to DHT is partly blocked, some of the testosterone that would have been consumed stays in circulation as testosterone. Think of it like damming a side channel in a river: the water that would have flowed through it backs up into the main stream. That backup is the reason testosterone levels tick upward on finasteride rather than falling.

The Modest Rise in Serum Testosterone

One of the most common worries among men starting finasteride is that it will tank their testosterone. The evidence says the opposite, though the effect is underwhelming in size. A meta-analysis pooling data from 11 studies and nearly 1,800 patients found that testosterone rose by an average of roughly 27 ng/dL during treatment. That’s a real, statistically detectable bump, but it’s small in clinical terms, often well within the normal day-to-day fluctuation your body already produces.

The increase wasn’t uniform, though. In men who started with low baseline testosterone, the rise was more noticeable. In men whose testosterone was already on the higher end, the researchers saw essentially no change. A separate trial in men with benign prostatic hyperplasia confirmed the same pattern: finasteride produced a modest but statistically significant testosterone increase compared to placebo, and the bump was greatest in men who had low levels to begin with.

⁴

The meta-analysis offered an interesting explanation for why the increase shows up more clearly in low-testosterone men. When DHT drops, a carrier protein called sex hormone-binding globulin (SHBG) has fewer DHT molecules to bind. That frees up binding capacity on SHBG, which then captures and “traps” circulating testosterone. In men who already have plenty of testosterone saturating their SHBG, there isn’t much room for this effect. In men with less testosterone in circulation, the newly available SHBG binding sites can measurably shift the numbers on a blood test, even though the total pool of androgens in the body hasn’t dramatically changed.

The Much Larger Drop in DHT

While the testosterone bump is subtle, the DHT reduction is dramatic. At the standard 1 mg dose used for hair loss, serum DHT falls by about 70%. A dose-response study in men with hair loss measured this across several dosage levels and found that serum DHT dropped roughly 50% even at very low doses, climbing to about 72% at the 5 mg dose used for prostate conditions.

⁵

In scalp tissue specifically, DHT levels fell by about 64% at the 1 mg dose. This distinction between what happens in the blood and what happens in tissue matters, because hair follicles respond to local DHT concentrations. The drug’s therapeutic effect on hair loss comes from that local reduction, not from the minor testosterone increase in the bloodstream.

⁵

What Happens to Estrogen

Testosterone doesn’t only convert into DHT. A separate enzyme called aromatase converts a portion of it into estradiol, a form of estrogen. When finasteride blocks the DHT pathway, more testosterone is available for aromatase to act on. The result is a measurable increase in estrogen levels. Data from a large nested study within the Prostate Cancer Prevention Trial found that after three years on finasteride, estrone rose by about 12% and estradiol by about 9%.

⁶

These are not huge shifts, and the same study found no link between these estrogen changes and prostate cancer risk. But they are worth knowing about, especially for men who are already tracking their hormone panels closely. A 9% rise in estradiol on its own rarely causes symptoms in men with otherwise normal hormonal profiles, but it could theoretically compound with other factors in men who are already on the higher end of normal estrogen.

Mixed Signals From the Pituitary

When hormone levels shift, the pituitary gland often adjusts its own output to compensate. The pituitary releases LH and FSH, which signal the testes to produce testosterone. You might expect that if testosterone rises on finasteride, the pituitary would dial those signals down. The evidence here is genuinely mixed.

One study in men taking 5 mg daily found that LH dropped by about 16% and FSH by about 24% over six months, alongside a 15% rise in testosterone and a 60% drop in DHT.

⁷ But a different study, which tested healthy young men on the same 5 mg dose for 28 days, found no significant change in either LH or FSH, even while DHT plummeted.

⁸

The broader meta-analysis of 5-alpha reductase inhibitors also found no significant changes in LH, FSH, or estradiol across ten studies that measured these hormones, suggesting that the pituitary feedback system largely stays put for most men on finasteride.

³ The discrepancy between studies may come down to patient age, baseline hormone levels, and how long patients were observed. In practical terms, finasteride does not appear to significantly disrupt the pituitary-gonadal axis for most users.

Does Age Change the Hormonal Response

Age plays a role in how the hormonal picture shifts. A study comparing finasteride’s effects in men above and below age 26 found that younger men started with higher DHT levels and experienced a more pronounced 50% DHT reduction over 12 months, with most of the drop occurring in the first six months. That steeper decline ran parallel with better clinical outcomes for hair regrowth.

⁹

Older men, meanwhile, saw a significant 20% drop in PSA at the one-year mark. This doesn’t directly indicate a different testosterone response, but it reflects the fact that finasteride’s downstream effects on androgen-sensitive tissue can vary with age. The testosterone increase itself, as noted earlier, is more apparent in men whose baseline levels are lower, a group that skews older on average.

Topical Finasteride and Systemic Hormones

Topical formulations of finasteride are increasingly popular because they promise a local effect on the scalp without flooding the whole body with the drug. A systematic review of topical finasteride studies found that while both scalp and blood DHT levels dropped significantly, serum testosterone levels did not change.

¹⁰

This makes pharmacological sense: less drug reaches the bloodstream, so less systemic enzyme inhibition occurs. For men who want to treat hair loss while keeping their systemic hormone profile untouched, topical application appears to achieve that, at least for testosterone. Some systemic DHT suppression still occurs with topical use, but it’s reduced compared to oral dosing.

Muscle, Strength, and Body Composition

A common fear among men, especially those who exercise seriously, is that blocking DHT will sabotage their muscle gains. The evidence is reassuring on this front. A year-long randomized trial gave older men with low testosterone either testosterone therapy alone or testosterone plus finasteride. Both groups gained roughly the same amount of lean mass (about 3.6 to 3.8 kg), lost similar amounts of fat, and saw comparable improvements in grip strength and physical performance.

¹¹

A follow-up trial confirmed that finasteride did not alter any of testosterone’s benefits on upper and lower body strength, fat-free mass, or bone mineral density. The researchers concluded that DHT is not required for testosterone’s musculoskeletal effects; it primarily mediates prostate enlargement.

¹²

This is worth emphasizing because the gym-culture anxiety around finasteride is widespread and mostly unfounded. Testosterone itself drives the anabolic effects people care about, and finasteride leaves testosterone untouched or slightly elevated. DHT contributes to some androgenic effects like body hair and prostate growth, but skeletal muscle doesn’t seem to need it.

Neurosteroids and Brain Chemistry

5-alpha reductase doesn’t only act on testosterone. It also converts progesterone into allopregnanolone, a neurosteroid that enhances the activity of GABA receptors in the brain. GABA is the nervous system’s main calming signal, so allopregnanolone essentially acts as a natural anxiolytic. When finasteride blocks 5-alpha reductase, it reduces allopregnanolone levels in the brain as well.

Animal research has confirmed this effect is substantial. In mice, finasteride caused a large and significant decrease in brain allopregnanolone content.

¹³ A separate rat study found that finasteride dose-dependently blocked stress-induced elevations in allopregnanolone, and at higher doses nearly depleted it from the brain entirely.

¹⁴

This neurosteroid angle is one reason some researchers have looked into whether finasteride contributes to mood changes, anxiety, or depression in a subset of users. The sexual side effects reported by some men, including reduced libido and erectile difficulties, have also drawn attention.

¹⁵ The extent to which neurosteroid depletion contributes to these complaints, versus other mechanisms, remains unclear. But it’s a reminder that finasteride’s hormonal effects go well beyond the testosterone-to-DHT conversion that gets the most attention.

What Happens After You Stop

Finasteride’s enzyme inhibition is reversible. Once you stop taking it, 5-alpha reductase activity resumes, and the hormonal changes associated with the drug begin to normalize. A follow-up assessment of men 60 weeks after discontinuation found no lasting changes in testosterone or gonadotropin levels.

¹⁶

Prostate volume, which shrinks during treatment, returned to its previous size. DHT levels rebound as the enzyme becomes active again, and hair loss will typically resume if finasteride was being used for that purpose. The hormonal system, in short, reverts to its pre-treatment state for the vast majority of users.

A small group of men report persistent symptoms after discontinuation, sometimes called post-finasteride syndrome. These reports include ongoing sexual difficulties, mood changes, and cognitive complaints. Whether these represent a genuine drug-induced lasting change or reflect other factors is actively debated, but the hormonal labs in these men typically return to normal ranges, which complicates any straightforward hormonal explanation.

Why Finasteride Shows Up on Anti-Doping Lists

Finasteride is prohibited by the World Anti-Doping Agency, though not because it enhances performance. Its ability to alter the breakdown products of steroids in urine makes it useful as a masking agent. Because 5-alpha reductase is responsible for producing many of the metabolites that drug testers look for, blocking the enzyme can suppress the urinary excretion of telltale steroid byproducts. Administration studies have shown that finasteride significantly reduced levels of key urinary markers and suppressed excretion of norandrosterone, a metabolite of the banned steroid norandrostenedione, by up to 84%.

¹⁷

For athletes subject to drug testing, this means finasteride use can trigger a violation regardless of intent. The ban isn’t about the testosterone bump or the DHT drop; it’s about how finasteride scrambles the metabolic fingerprints that testers rely on to catch steroid abuse.

Finasteride in Gender-Affirming Hormone Therapy

Finasteride sometimes appears in discussions of gender-affirming care for transfeminine individuals. The logic is straightforward: if the goal is to minimize the effects of androgens, and finasteride reduces DHT, it should be helpful on top of standard estrogen and anti-androgen regimens. In practice, the added benefit is uncertain. Once testosterone has already been suppressed to female-typical levels using standard therapy, the additional reduction in DHT from finasteride may not produce meaningful clinical improvement.

¹⁸

For transmasculine individuals taking testosterone, finasteride is occasionally used to mitigate androgenic side effects like scalp hair loss while preserving the desired masculinizing effects of testosterone on body composition and voice. The body composition data from cisgender men on combined testosterone and finasteride supports the idea that blocking DHT does not undermine testosterone’s anabolic effects, which is relevant for anyone in this situation.

¹²

1
PubMed. Finasteride: a slow-binding 5 alpha-reductase inhibitor
2
Journal of Drug Delivery and Therapeutics. A Review on Finasteride: A 5-Alpha Reductase Inhibitors, its Mechanism, Facts and Benefits
3
Sexual Medicine Reviews. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results
4
PubMed. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia
5
Journal of the American Academy of Dermatology. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia
6
PubMed Central. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case–control study
7
PubMed. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study
8
The Journal of Clinical Endocrinology & Metabolism. Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men
9
PubMed. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old
10
PubMed Central. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women
11
The Journal of Clinical Endocrinology & Metabolism. Exogenous Testosterone Alone or with Finasteride Increases Physical Performance, Grip Strength, and Lean Body Mass in Older Men with Low Serum T
12
PubMed Central. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial
13
Brain Research. Lack of evidence of a role for the neurosteroid allopregnanolone in ethanol-induced reward and c-fos expression in DBA/2 mice
14
PubMed. Studies on neurosteroids XXV. Influence of a 5alpha-reductase inhibitor, finasteride, on rat brain neurosteroid levels and metabolism
15
The Journal of Sexual Medicine. Adverse Side Effects of 5α-Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
16
Anais Brasileiros de Dermatologia. Post-finasteride syndrome
17
PubMed. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite
18
PubMed. Is there a role for 5α-reductase inhibitors in transgender individuals?